The impact of mir204 on drug resistance in recurrent ovarian cancer patients and exploration of population treatment strategies
Objective To explore the therapeutic effect of mir204 on patients with recurrent ovarian cancer.Methods 240 patients with recurrent ovarian cancer from medical institutions were selected as the research subjects.Patients with recurrent and drug-resistant ovarian cancer were selected as the drug-resistant group,while patients with non resistant recurrence and no cancer were selected as the non drug-resistant group,with 120 patients in each group.Using a case-control study method,baseline information of first-time recurrent ovarian cancer patients was collected,and gene expression differences,treatment plans,and treatment outcomes between the two groups of patients were analyzed.Results There was a statistically significant difference between the two groups in terms of occupation,smoking,alcohol consumption,amenorrhea,use of hormone replacement therapy,and whether a first-degree relative had cancer(P＜0.05).There were 102 cases of increased expression of mir204 in the drug resistant group,and 7 cases of increased expression of mir204 in the non drug resistant group.The difference between the two groups was statistically significant(P＜0.05).Through cluster analysis and RT-PCR,it was found that mir204 is associated with the expression of PIK3CA,PIK3R1,PTEN,and AKT.The treatment effect of the non drug resistant group was better than that of the drug resistant group.Grouping analysis was conducted on the expression level of mir204,and it was found that the treatment effect of high expression of mir204 was worse than that of low expression of mir204(P＜0.05).Conclusion There are differences in the treatment regimen and efficacy of mir204 in patients with recurrent ovarian cancer,which may be related to the regulatory role of mir204 through the PI3K-AKT signaling pathway.
Recurrent ovarian cancerPlatinum resistanceMir204PI3K-AKT signaling pathwayOvarian cancer treatment
万方数据
维普
